These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6938021)

  • 21. [Changes in prostate-specific antigen in casodex (bicalutamide) monotherapy in a dose 150 mg/day given to patients with locally advanced and/or advanced prostatic cancer].
    Kariakin OB; Sviridova TV; Tsodikova LB; Grishin GN; Sergeeva TN; Perekhrest MA; Donichkina EA
    Urologiia; 2001; (4):26-9. PubMed ID: 11569230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of radioimmunoassay of human prostate-specific acid phosphatase in the diagnosis and follow-up of therapy in prostatic carcinoma.
    Vihko P; Lukkarinen O; Kontturi M; Vihko R
    Cancer Res; 1981 Mar; 41(3):1180-3. PubMed ID: 7459859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SMS 201-995 in the treatment of refractory prostatic carcinoma.
    Logothetis CJ; Hossan EA; Smith TL
    Anticancer Res; 1994; 14(6B):2731-4. PubMed ID: 7872709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Invasive disseminated aspergillosis in combined immunosuppressive therapy in systemic lupus erythematosus].
    Teuber G; Schwarting A; Mildenberger P; Schmidt-Brücken G; Moll R; Bornemann A; Wandel E; Wanitschke R; Meyer zum Büschenfelde KH
    Med Klin (Munich); 1996 Dec; 91(12):798-801. PubMed ID: 9082168
    [No Abstract]   [Full Text] [Related]  

  • 26. High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. A pilot study.
    Fosså SD; Jahnsen JU; Karlsen S; Ogreid P; Haveland H; Trovåg A
    Eur Urol; 1985; 11(1):11-6. PubMed ID: 3157571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
    Nicolini A; Mancini P; Ferrari P; Anselmi L; Tartarelli G; Bonazzi V; Carpi A; Giardino R
    Biomed Pharmacother; 2004 Oct; 58(8):447-50. PubMed ID: 15464874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
    Stathopoulos GP; Koutantos J; Vaslamatzis MM; Athanasiadis A; Papadopoulos G; Labrodimou G; Stathopoulos J; Rigatos S
    Oncol Rep; 2009 Aug; 22(2):345-8. PubMed ID: 19578775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of advanced metastasizing carcinoma of the prostate with estracyt (author's transl)].
    Rambausek M; Lutherer S; Terhorst B
    Urologe A; 1981 Jul; 20(4):223-7. PubMed ID: 7196632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.
    Apras S; Ertenli I; Ozbalkan Z; Kiraz S; Ozturk MA; Haznedaroglu IC; Cobankara V; Pay S; Calguneri M
    Arthritis Rheum; 2003 Aug; 48(8):2256-61. PubMed ID: 12905480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The clinical and prognostic value of inversion of the PSA/PAP ratio in prostatic cancer].
    Morote Robles J; Lorente JA; Reig C; López Pacios MA; de Torres JA; Soler Roselló A
    Actas Urol Esp; 1994 May; 18(5):559-61. PubMed ID: 7521563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of advanced prostate cancer with cyclophosphamide, doxorubicin, and methotrexate.
    Straus MJ; Fleit JP; Engelking C
    Cancer Treat Rep; 1982 Oct; 66(10):1797-802. PubMed ID: 7127321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis.
    Jani AB; Kao J; Hellman S
    Cancer; 2003 Dec; 98(11):2351-61. PubMed ID: 14635069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis].
    Tervaert JW; Stegeman CA
    Ned Tijdschr Geneeskd; 2003 Nov; 147(46):2265-7. PubMed ID: 14655291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The treatment of advanced prostatic carcinoma with medroxyprogesterone.
    Rafla S; Johnson R
    Curr Ther Res Clin Exp; 1974 Apr; 16(4):261-7. PubMed ID: 4208339
    [No Abstract]   [Full Text] [Related]  

  • 36. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis--report of three cases.
    Kanzler S; Gerken G; Dienes HP; Meyer zum Büschenfelde KH; Lohse AW
    Z Gastroenterol; 1997 Jul; 35(7):571-8. PubMed ID: 9273991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy.
    Tsuruya K; Harada A; Hirakata H; Mitsuiki K; Johko T; Kondoh H; Takechi S; Fujishima M
    Clin Nephrol; 2000 Jan; 53(1):1-9. PubMed ID: 10661476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate.
    Loening SA; Scott WW; deKernion J; Gibbons RP; Johnson DE; Pontes JE; Prout GR; Schmidt JD; Soloway MS; Chu TM; Gaeta JF; Slack NH; Murphy GP
    J Urol; 1981 Jun; 125(6):812-6. PubMed ID: 7017170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. External irradiation therapy in carcinoma of the prostate.
    Edsmyr F; Esposti PL; Andersson L
    Scand J Urol Nephrol Suppl; 1980; 55():213-7. PubMed ID: 6938028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
    Logothetis CJ; von Eschenbach AC; Samuels ML; Trindade A; Johnson DE
    Cancer Treat Rep; 1982 Jan; 66(1):57-63. PubMed ID: 7053267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.